Vivek Bhalla, MD, FASN, FAHA
@bhallaresearch.bsky.social
Exploring Molecular Mechanisms of Kidney Disease and Hypertension; Associate Professor, Stanford Medicine; Director, Stanford Hypertension Center; Director, Stanford Pre Renal Initiative; former Chair, Council on Kidney and Cardiovascular Disease, AHA
Great reference
September 12, 2025 at 5:53 AM
Great reference
Wanpen- interesting …do you have a reference? I believe baxdrostat is via CYP3A4? (Ie similar to eplerenone and tacrolimus, and therefore concerns with things like diltiazem and paxlovid)
April 24, 2025 at 10:30 PM
Wanpen- interesting …do you have a reference? I believe baxdrostat is via CYP3A4? (Ie similar to eplerenone and tacrolimus, and therefore concerns with things like diltiazem and paxlovid)
but this could change soon with ARCTIC, PACIFIC trials
Full disclosure: SABs for AZ, Bayer
Full disclosure: SABs for AZ, Bayer
April 24, 2025 at 6:02 AM
but this could change soon with ARCTIC, PACIFIC trials
Full disclosure: SABs for AZ, Bayer
Full disclosure: SABs for AZ, Bayer
aldosterone sensitivity, etc.
Regarding ASIs vs MRAs, I was a big believer in eplerenone with its fewer side effects but have accumulated more and more folks where it’s simply not potent enough. This creates a lane for ASIs. nsMRAs (possibly MRAs in general) still have the upper hand for GDMT 2/n
Regarding ASIs vs MRAs, I was a big believer in eplerenone with its fewer side effects but have accumulated more and more folks where it’s simply not potent enough. This creates a lane for ASIs. nsMRAs (possibly MRAs in general) still have the upper hand for GDMT 2/n
April 24, 2025 at 6:02 AM
aldosterone sensitivity, etc.
Regarding ASIs vs MRAs, I was a big believer in eplerenone with its fewer side effects but have accumulated more and more folks where it’s simply not potent enough. This creates a lane for ASIs. nsMRAs (possibly MRAs in general) still have the upper hand for GDMT 2/n
Regarding ASIs vs MRAs, I was a big believer in eplerenone with its fewer side effects but have accumulated more and more folks where it’s simply not potent enough. This creates a lane for ASIs. nsMRAs (possibly MRAs in general) still have the upper hand for GDMT 2/n
Very exciting news…..success with this broad cohort continues a slow and steady march for blockade of aldosterone signaling as a major tool in hypertension more broadly (not just obvious cases of PA) by likely capturing common cases of subclinical PA, aldosterone dysregulation, 1/n
April 24, 2025 at 6:02 AM
Very exciting news…..success with this broad cohort continues a slow and steady march for blockade of aldosterone signaling as a major tool in hypertension more broadly (not just obvious cases of PA) by likely capturing common cases of subclinical PA, aldosterone dysregulation, 1/n